Skip to main content
European Commission logo print header

Remote Assessment of Disease and Relapse – Alzheimer’s Disease

Project description

New platform for early diagnosis of Alzheimer’s disease

The estimation of functional decline in early Alzheimer’s disease (AD) is crucial for the treatment of patients. The EU-funded RADAR-AD project will develop a digital platform to discover minuscule functional deficits in early AD patients. The platform will integrate a combination of smartphone, wearable and home sensor-based parameters adequate for longitudinal studies and tests, identify the most relevant functional domains and the most encouraging remote measurement tools (RMTs). It will test the platform and selected RMTs in a real-world environment consisting of 240 participants, and perform statistical modelling to assess longitudinal predictions. RADAR-AD will discuss the results with regulatory agencies, patients and carer groups to acquire knowledge and guidance for future treatments.


There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful combination of smartphone, wearable and/or home sensor based parameters. The system developed will be suitable for future longitudinal studies, including trials. The objectives are to 1) Identify the most relevant functional domains and the most promising remote measurement tools (RMTs) for these domains based on reviewing the literature and piloting of RMTs in small studies; 2) Optimise the RADAR-CNS platform for use in AD studies; 3) Test the platform and selected RMTs in a real world environment clinical study with 240 participants across the AD spectrum ranging from the preclinical AD to the dementia stage; 4) Perform statistical modelling to estimate longitudinal predictions; 5) Discuss results with regulatory agencies in order to obtain guidance about how to develop a path for formal qualification as outcome measurements in future therapeutic interventions. Considering the limited budget and project duration, we will rely upon already available technology platforms and on available longitudinal datasets where possible. The consortium includes experts in clinical dementia studies, computer science, bioinformatics, regulatory policies, ethics, and patient and public involvement (PPI). Additional strengths of the consortium are the deep and broad interface with RADAR-CNS and related IMI projects, and the access to large amount of patient-level data from key European cohort studies for modelling purposes.


Net EU contribution
€ 882 041,25
WC2R 2LS London
United Kingdom

See on map

London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Total cost
€ 1 100 337,53

Participants (16)